Dianhydrogalactitol is a Small Molecule owned by Kintara Therapeutics, and is involved in 7 clinical trials, of which 4 were completed, and 3 are ongoing.

Dianhydrogalactitol (VAL-083) acts as an alkylating agent. Alkylating agents work by different mechanisms. The attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription. The drug candidate causes disruption of DNA function and cell death. It stops tumor growth by cross-linking guanine bases in DNA double-helix strands directly attacking DNA. It adds methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. The drug candidate also attacks the tumor's DNA at a different location and in a different way, rapidly forming durable cross links at the N7-position of guanine.  These cross-links are not repaired by the DNA repair enzyme (MGMT).

The revenue for Dianhydrogalactitol is expected to reach a total of $6.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Dianhydrogalactitol NPV Report.

Dianhydrogalactitol is currently owned by Kintara Therapeutics.

Dianhydrogalactitol Overview

Dianhydrogalactitol (VAL-083/Dag) is under development for the treatment of MGMT-unmethylated GBM, diffuse intrinsic pontine glioma, bevacizumab-naive recurrent glioblastoma multiforme, medulloblastoma, high-grade glioma, relapsed and refractory non-small cell lung cancer, cervical cancer, ovarian cancers, brain tumour and other solid tumours (bladder cancer and head and neck cancer). It is formulated as the injection for intravenous administration. It was under development for recurrent glioblastoma multiforme (GBM), gliosarcoma.

Kintara Therapeutics Overview

Kintara Therapeutics (DelMar) formerly DelMar Pharmaceuticals Inc, is a clinical stage drug development bio pharmaceutical company. It is engaged in the development and commercialization of new cancer therapies. The company offers VAL-083, a small molecule chemotherapy used for the treatment of refractory glioblastoma multiforme(GMB) of brain cancer. Kintara also explores VAL-083 as a therapy for solid tumors and front-line GBM including ovarian cancer and non-small cell lung cancer (NSCLC). The company offers its produts and services to lung cancer, ovarian cancer, chronic myeloid leukemia, brain cancers, and lung cancer. Kintara provides warrants services, pre-clinical testing, and clinical trials, among others. It also conducts research and development on cancer indications. It has operations in the US and Canada. Kintara Pharmaceuticals is headquartered in San Diego, California, United States.

The operating loss of the company was US$22.7 million in FY2022, compared to an operating loss of US$38.2 million in FY2021. The net loss of the company was US$22.7 million in FY2022, compared to a net loss of US$38.3 million in FY2021.

Quick View – Dianhydrogalactitol

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Dianhydrogalactitol
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
  • Sponsor Company: Kintara Therapeutics
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.